Covance To Present At The Lazard Capital Markets 9th Annual Healthcare Conference

    Covance To Present At The Lazard Capital Markets 9th Annual Healthcare

PR Newswire

PRINCETON, N.J., Nov. 12, 2012

PRINCETON, N.J., Nov. 12, 2012 /PRNewswire/ --Covance Inc. (NYSE: CVD) today
announced that it will present at the Lazard Capital Markets 9^th Annual
Healthcare Conference on Wednesday, November 14, 2012 at 1:30 p.m. (ET).
Investors may access a live webcast of the presentation at
In order to register and download any necessary software, please log on 10
minutes early.

Covance, with headquarters in Princeton, New Jersey, is one of the world's
largest and most comprehensive drug development services companies with annual
revenues greater than $2 billion, global operations in more than 30 countries,
and 11,500 employees worldwide. Information on Covance's products and
services, recent press releases, and SEC filings can be obtained through its
website at

Statements contained in this press release, which are not historical facts,
such as statements about prospective earnings, savings, revenue, operations,
revenue and earnings growth and other financial results are forward-looking
statements pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. All such forward-looking statements including
the statements contained herein regarding anticipated trends in the Company's
business are based largely on management's expectations and are subject to and
qualified by risks and uncertainties that could cause actual results to differ
materially from those expressed or implied by such statements. These risks
and uncertainties include, without limitation, competitive factors,
outsourcing trends in the pharmaceutical industry, levels of industry research
and development spending, the Company's ability to continue to attract and
retain qualified personnel, the fixed price nature of contracts or the loss or
delay of large studies, risks associated with acquisitions and investments,
the Company's ability to increase order volume, the pace of translation of
orders into revenue in late-stage development services, testing mix and
geographic mix of kit receipts in central laboratories, fluctuations in
currency exchange rates, the realization of savings from the Company's
announced restructuring actions, the cost and pace of completion of our
information technology projects and the realization of benefits therefrom,
and other factors described in the Company's filings with the Securities and
Exchange Commission including its Annual Report on Form 10-K and Quarterly
Reports on Form 10-Q. The Company undertakes no duty to update any
forward-looking statement to conform the statement to actual results or
changes in the Company's expectations.

SOURCE Covance Inc.

Contact: Investor Relations, +1-609-452-4807
Press spacebar to pause and continue. Press esc to stop.